West Pharmaceutical Services (United States)
WST
$366.48
-1.65%
West Pharmaceutical Services is a Pennsylvania-based supplier of elastomer-based packaging components, nonglass containment solutions, and auto-injectors for injectable drugs, serving pharmaceutical, biotechnology, and generic drug manufacturers across large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company operates as a critical, high-margin picks-and-shovels supplier to the injectable drug supply chain, reporting through two segments — Proprietary Products (roughly 80% of revenue) and Contract-Manufactured Products (about 20%) — with approximately 55% of revenue generated internationally. The current investor narrative centers on West's role as a primary beneficiary of the GLP-1 and biologics boom, evidenced by the company lifting annual guidance after strong GLP-1-driven growth in Q1 2026 and delivering 13.85% year-over-year revenue growth in Q2 2026. Sentiment has been further reinforced by a wave of analyst upgrades, including Morgan Stanley's move to Overweight in September 2026 and Barclays' upgrade to Overweight in June 2026, though debate persists around the stock's premium valuation and whether GLP-1-driven demand is fully priced in.…
WST
West Pharmaceutical Services (United States)
$366.48
Related headlines
Investment Opinion: Should I buy WST Today?
Based on the synthesized data, West Pharmaceutical warrants a Buy rating for investors with a medium-to-long-term horizon and tolerance for volatility. The core thesis is that West is a high-quality, picks-and-shovels supplier to the injectable drug supply chain, benefiting from structural GLP-1 and biologics demand, with accelerating revenue growth (13.85% YoY in Q2 2026) and a strong buy consensus from 16 analysts (mean recommendation 1.35) with an average target price of $407.56, implying 11.7% upside. The company's exceptional balance sheet (debt-to-equity 0.131, current ratio 3.02) and robust free cash flow ($436.9M trailing) support continued investment and shareholder returns.
Supporting evidence includes: 1) Revenue reacceleration to 13.85% YoY in Q2 2026 from mid-single-digit growth in prior periods, driven by GLP-1 demand; 2) Profitability with a 37.74% gross margin, 20.09% operating margin, and 15.54% ROE, though operating margin compressed from 25.86% in Q1 2026; 3) Valuation at 40.28x trailing PE and 36.56x forward PE, which is a premium to the sector but below the stock's historical peak multiples (59.22x PE in 2021); 4) Analyst target upside of 11.7% to the average target, with a high target of $459.00 implying 25.8% upside; and 5) Strong free cash flow yield of 2.2% and a low payout ratio of 12.4%, providing flexibility for buybacks and dividends.
The biggest risks that could invalidate the thesis are: 1) A sustained deceleration in GLP-1 demand or pricing pressure, which could slow revenue growth below 10%; 2) Further operating margin compression below 20%, which would challenge the premium valuation; and 3) A broader healthcare sector de-rating or market rotation away from high-multiple growth stocks. The rating would upgrade to a Strong Buy if revenue growth accelerates above 15% and operating margins stabilize above 22%, or downgrade to Hold if revenue growth falls below 8% or operating margins drop below 18%. Relative to its history and peers, West appears fairly valued to slightly undervalued on a historical basis, but premium on a peer basis; the stock's valuation is justified by its superior growth and profitability, but leaves little room for error.
Sign up to view all
WST 12-Month Price Forecast
West Pharmaceutical presents a compelling growth story as a critical supplier to the GLP-1 and biologics boom, with accelerating revenue growth and a strong analyst consensus. The company's premium valuation is supported by its high margins, strong balance sheet, and entrenched competitive position, though it leaves little room for execution missteps. The recent operating margin compression in Q2 2026 bears watching, but is likely seasonal. I would upgrade to high confidence if operating margins stabilize above 22% and revenue growth exceeds 15%, and downgrade to neutral if revenue growth falls below 10% or margins compress below 18%. The risk-reward skews favorably for long-term investors willing to tolerate volatility, given the structural demand drivers and the stock's historical valuation range.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on West Pharmaceutical Services (United States)'s 12-month outlook, with a consensus price target around $411.00 and implied upside of +12.2% versus the current price.
Average Target
$411.00
0 analysts
Implied Upside
+12.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$340 - $459
Analyst target range
West Pharmaceutical is covered by 16 analysts, and the consensus recommendation is a strong buy with a recommendation mean of 1.35 (where 1.0 is a strong buy and 5.0 is a strong sell), reflecting broad institutional conviction. The average price target is $407.56, which implies approximately 11.7% upside from the current price of $364.98, while the consensus EPS estimate of $14.01 and revenue estimate of $4.42 billion point to continued double-digit growth. The bullish tilt is corroborated by recent institutional actions, including Morgan Stanley's upgrade to Overweight on September 22, 2026, Barclays' upgrade to Overweight on June 9, 2026, and reiterated Buy/Outperform ratings from UBS, Citigroup, Evercore ISI, and KeyBanc throughout 2026. The target range spans from a low of $340.00 to a high of $459.00, a spread of $119 (roughly 35% of the low target), which signals meaningful dispersion in analyst expectations. The high target of $459.00 implies about 25.8% upside and likely assumes sustained GLP-1-driven volume growth, margin expansion from proprietary product mix, and multiple expansion as the market rewards West's structural positioning. The low target of $340.00 sits about 6.8% below the current price and likely prices in margin compression, slower-than-expected GLP-1 adoption, or broader healthcare sector de-rating. Notably, the low target is below the current price, indicating that even the most cautious analyst sees limited downside, and the clustering of targets above the current price with a strong buy consensus suggests the risk-reward skews favorably for investors willing to accept the stock's 1.135 beta and premium valuation.
Bulls vs Bears: WST Investment Factors
The bull case currently has stronger evidence, supported by accelerating revenue growth (13.85% YoY in Q2 2026), a strong buy consensus from 16 analysts with an average target of $407.56 (11.7% upside), and an exceptionally strong balance sheet with debt-to-equity of 0.131. However, the bear case is not without merit: operating margin compression to 20.53% in Q2 2026, a premium valuation at 40.28x trailing PE, and a stagnant 3-month price performance (-0.21%) suggest the stock may be priced for perfection. The single most important tension is whether GLP-1-driven demand is fully priced into the stock's premium multiple — if demand continues to accelerate and margins stabilize, the stock could break through its 52-week high of $386.00; if growth decelerates or margins compress further, the premium valuation could unwind sharply.
Bullish
- GLP-1-driven revenue reacceleration: Q2 2026 revenue grew 13.85% YoY to $872.3M, up from $766.2M in Q2 2025, marking a clear reacceleration from mid-single-digit growth in prior periods. Management raised annual guidance after strong GLP-1-driven growth in Q1 2026, and the Proprietary Products segment contributed $722.6M, confirming the high-margin franchise is the primary growth engine.
- Strong analyst consensus and upside: 16 analysts rate the stock a strong buy with a mean recommendation of 1.35, and the average price target of $407.56 implies 11.7% upside from $364.98. Recent upgrades from Morgan Stanley (Overweight, Sept 2026) and Barclays (Overweight, June 2026) reinforce institutional conviction.
- Exceptional balance sheet and cash generation: Debt-to-equity is just 0.131 and the current ratio is 3.02, providing substantial financial flexibility. Trailing free cash flow of $436.9M against a $19.9B market cap yields 2.2%, and the company returned $297.6M via buybacks and $15.7M in dividends in Q2 2026 alone.
- Valuation below historical peak multiples: The trailing PE of 40.28x sits in the lower half of its multi-year band (vs. 59.22x in 2021 and 40x-53x in 2024), while the PS ratio of 6.47x is near the bottom of its historical range versus 29x-48x in 2021-2024. If GLP-1 demand sustains, the current multiple could prove conservative relative to West's own history.
Bearish
- Premium valuation leaves little room for error: At 40.28x trailing PE, 36.56x forward PE, and 26.97x EV/EBITDA, West trades at a significant premium to typical medical instruments sector averages (high-teens to low-twenties PE, low-to-mid-teens EV/EBITDA). Any execution miss or GLP-1 demand disappointment could trigger sharp multiple compression.
- Operating margin compression in Q2 2026: Operating margin fell to 20.53% in Q2 2026 from 25.86% in Q1 2026 and 26.02% in Q4 2025, driven by higher SG&A of $117.6M and seasonality in cost absorption. Gross margin also compressed modestly to 37.74% from 37.75% in Q4 2025, signaling potential cost pressures.
- Stagnant 3-month price performance: Despite strong 1-month (+6.52%) and 6-month (+43.24%) returns, the stock is down 0.21% over the past 3 months versus the S&P 500's +3.34%, producing a negative 3-month relative strength of -3.55. This consolidation near the 52-week high of $386.00 suggests limited near-term headroom.
- High beta and drawdown risk: With a beta of 1.135, West is roughly 13.5% more volatile than the broader market, and its maximum drawdown of -24.83% over the period underscores meaningful downside swings. The stock's 52-week range spans $162 (from $223.83 to $386.00), highlighting the potential for large price moves.
WST Technical Analysis
West Pharmaceutical is in a sustained uptrend, with the stock up 33.61% over the past year and 32.05% year-to-date, decisively outperforming the S&P 500's 15.01% and 12.86% respective gains. At a current price of $364.98, the stock sits at approximately 87% of its 52-week range (52-week low of $223.83, high of $386.00), positioning it near the upper end of its annual band — a sign of persistent momentum but also of limited near-term headroom to the prior high. The 52-week range spans roughly $162, and the stock's location near the top suggests buyers remain in control, though the proximity to resistance warrants vigilance for exhaustion signals. Recent momentum is positive but decelerating: the stock is up 6.52% over the past month versus the S&P 500's 0.59%, a relative strength of +5.93 percentage points, yet the 3-month change is essentially flat at -0.21% against the S&P's +3.34%, producing a negative 3-month relative strength of -3.55. This divergence — strong 1-month and 6-month (+43.24%) performance bracketing a stagnant 3-month stretch — suggests the stock consolidated through the summer after a sharp spring rally, with the July 24 drop from $355.48 to $328.20 marking a notable single-session drawdown before the recovery resumed. The 6-month relative strength of +25.89 percentage points confirms West has been a standout performer over the intermediate term, and the recent 1-month reacceleration hints the consolidation may be resolving to the upside. Key technical levels are defined by the 52-week high of $386.00 as resistance and the 52-week low of $223.83 as major support, with the stock having recovered 63% from that low. A breakout above $386 would signal a fresh leg higher and likely draw momentum buyers, while a breakdown below the $340-$350 zone (where the stock found support in late August and early September) would threaten the uptrend structure. With a beta of 1.135, West is roughly 13.5% more volatile than the broader market, and its maximum drawdown of -24.83% over the period underscores that position sizing should account for meaningful downside swings despite the stock's quality profile.
Beta
1.13
1.13x market volatility
Max Drawdown
-24.8%
Largest decline past year
52-Week Range
$224-$386
Price range past year
Annual Return
+37.8%
Cumulative gain past year
| Period | WST Return | S&P 500 |
|---|---|---|
| 1m | +7.8% | +0.9% |
| 3m | +2.5% | +3.4% |
| 6m | +42.8% | +14.4% |
| 1y | +37.8% | +16.2% |
| ytd | +32.6% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WST Fundamental Analysis
West's revenue trajectory is clearly accelerating: Q2 2026 revenue reached $872.3 million, up 13.85% year-over-year from $766.2 million in Q2 2025, and up sequentially from $844.9 million in Q1 2026. The multi-quarter trend shows consistent expansion — revenue climbed from $698.2 million in Q1 2025 to $804.3 million in Q3 2025, $805.0 million in Q4 2025, $844.9 million in Q1 2026, and $872.3 million in Q2 2026 — with the year-over-year growth rate in Q2 2026 (13.85%) marking a notable reacceleration versus the mid-single-digit comparisons of prior periods. Segment data shows Proprietary Products contributing $722.6 million and West Vantage $149.7 million, confirming that the high-margin proprietary franchise remains the dominant growth engine, consistent with the GLP-1 and biologics demand narrative. This accelerating top-line momentum, reinforced by management's raised annual guidance, supports a constructive investment case built on durable, structurally driven demand rather than cyclical recovery. Profitability remains robust, with Q2 2026 net income of $154.0 million on a 17.65% net margin and a 37.74% gross margin, though the gross margin compressed modestly from 37.75% in Q4 2025 and 36.49% in Q3 2025. Operating income of $179.1 million produced a 20.53% operating margin, down from 25.86% in Q1 2026 and 26.02% in Q4 2025, reflecting the seasonality of cost absorption and higher SG&A of $117.6 million in Q2. The trailing valuation metrics show a net margin of 16.06% and operating margin of 20.09%, healthy for the medical instruments and supplies industry, and the company has remained solidly profitable across every quarter in the dataset, with net income ranging from $89.8 million (Q1 2025) to $154.0 million (Q2 2026). The balance sheet is exceptionally strong: debt-to-equity stands at just 0.131, the current ratio is 3.02, and the company generated $436.9 million in trailing free cash flow against a $19.9 billion market cap, implying an FCF yield of roughly 2.2%. Q2 2026 operating cash flow was $124.0 million with capital expenditure of $43.2 million, yielding $80.8 million in free cash flow, while the company returned capital via $297.6 million in stock repurchases and $15.7 million in dividends. With ROE of 15.54% and ROA of 11.38%, West demonstrates efficient capital deployment and self-funding growth capacity, and its low leverage and $435.8 million cash balance provide ample flexibility for continued buybacks and organic investment.
Quarterly Revenue
$872300000.0B
2026-06
Revenue YoY Growth
+13.9%
YoY Comparison
Gross Margin
37.7%
Latest Quarter
Free Cash Flow
$436900000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WST Overvalued?
Because West Pharmaceutical is solidly profitable — Q2 2026 net income of $154.0 million and trailing EPS of $2.17 — the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of 40.28x and a forward PE of 36.56x, and the gap between the two implies the market expects meaningful earnings growth over the next twelve months, consistent with analyst consensus EPS estimates of $14.01. The PEG ratio of 33.99 appears distorted by a low near-term growth denominator, but the forward PE compression from 40.3x to 36.6x signals that earnings are expected to grow faster than the share price, a constructive setup if execution holds. Relative to the broader medical instruments and supplies sector, West's trailing PE of 40.28x and forward PE of 36.56x represent a premium, and its price-to-sales ratio of 6.47x and EV/EBITDA of 26.97x are elevated versus typical industry averages in the high-teens to low-twenties for PE and low-to-mid-teens for EV/EBITDA. This premium is partially justified by West's superior profitability — a 37.74% gross margin, 20.09% operating margin, and 15.54% ROE — and its entrenched competitive position as a critical supplier to high-growth biologics and GLP-1 franchises, though the 26.97x EV/EBITDA multiple leaves little room for execution missteps. The price-to-book ratio of 6.26x and price-to-cash-flow of 26.35x further underscore that investors are paying up for quality and growth durability. Historically, West's valuation has compressed significantly from its 2021 peak, when the PE ratio reached 59.22x and the PS ratio hit 47.93x, and even from 2024 levels when the PE ranged from 40x to 53x and PS from 29x to 34x. The current trailing PE of 40.28x sits in the lower half of its multi-year band, while the PS ratio of 6.47x is near the bottom of its historical range — a striking contrast to the 29x-48x PS readings of 2021-2024. This suggests the market is no longer pricing in the hyper-growth premium of the pandemic era, and if revenue growth continues to accelerate on GLP-1 demand, the current multiple could prove conservative relative to the company's own history.
PE
40.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 30x~53x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.0x
Enterprise Value Multiple
Investment Risk Disclosure
West Pharmaceutical's financial and operational risks are relatively contained given its strong balance sheet, but margin trends warrant attention. The company's debt-to-equity of 0.131 and current ratio of 3.02 provide a solid cushion, and trailing free cash flow of $436.9M demonstrates self-funding capacity. However, operating margin compressed to 20.53% in Q2 2026 from 25.86% in Q1 2026 and 26.02% in Q4 2025, driven by higher SG&A of $117.6M and seasonality. Gross margin also edged down to 37.74% from 37.75% in Q4 2025, and any sustained margin erosion could pressure earnings growth, especially given the stock's premium valuation. Additionally, revenue concentration in the Proprietary Products segment (roughly 80% of revenue) and dependence on GLP-1 demand create vulnerability if that therapeutic category faces pricing pressure or regulatory changes.
Market and competitive risks are significant given West's premium valuation and high beta. The stock trades at 40.28x trailing PE and 26.97x EV/EBITDA, well above typical medical instruments sector averages, leaving little room for execution missteps. With a beta of 1.135, West is more volatile than the broader market, and its maximum drawdown of -24.83% over the period highlights the potential for sharp declines during market rotations. Competitive threats include alternative drug delivery technologies or in-house solutions by major pharmaceutical clients, though West's entrenched position and high switching costs mitigate this. Recent news highlights sector-specific risks: CooperCompanies' Q3 revenue miss on U.S. inventory destocking sent its shares down 16% after-hours, a reminder that supply chain inventory adjustments can impact medical device suppliers. While West was cited as a better-ranked alternative, the broader sector faces destocking and competition headwinds.
The worst-case scenario for West would involve a combination of GLP-1 demand deceleration, margin compression, and multiple contraction. If GLP-1 adoption slows or pricing pressure intensifies, revenue growth could decelerate from 13.85% to mid-single digits, and operating margins could fall below 20%, triggering a de-rating. In this scenario, the stock could retest its 52-week low of $223.83, representing a 38.7% decline from the current price of $364.98. Even a moderate bear case, aligned with the analyst low target of $340.00, implies a 6.8% downside. A more severe scenario, such as a broader healthcare sector de-rating or a significant competitive disruption, could push the stock toward $300, a 17.8% decline. Investors should note that the stock's high beta and premium valuation amplify downside risk in adverse market conditions.
FAQ
The key risks of holding WST, ranked by severity, are: 1) Valuation risk: at 40.28x trailing PE and 26.97x EV/EBITDA, the stock is priced for perfection, and any earnings miss or growth deceleration could trigger a sharp de-rating. 2) Margin compression risk: operating margin fell to 20.53% in Q2 2026 from 25.86% in Q1 2026, and further compression could pressure earnings. 3) GLP-1 demand concentration: roughly 80% of revenue comes from Proprietary Products, and a slowdown in GLP-1 adoption or pricing pressure could significantly impact growth. 4) Macro and market risk: with a beta of 1.135, the stock is more volatile than the market, and a sector rotation away from high-multiple healthcare stocks could lead to underperformance. The maximum drawdown of -24.83% illustrates the potential for significant losses in adverse conditions.
The 12-month forecast for WST includes three scenarios: Bull case (25% probability) with a target range of $430-$459, driven by GLP-1 demand exceeding expectations and margin expansion; Base case (55% probability) with a target range of $380-$420, assuming steady revenue growth in the low-to-mid teens and stable margins; and Bear case (20% probability) with a target range of $300-$340, triggered by GLP-1 demand deceleration and margin compression. The base case is most likely, supported by the analyst average target of $407.56 and consensus EPS of $14.01. The key assumption behind the base case is that revenue growth remains in the 10-14% range and operating margins stabilize around 20-21%. A breakout above the 52-week high of $386.00 would signal the bull case, while a breakdown below $340 would indicate the bear case.
WST appears fairly valued to slightly undervalued relative to its own history, but premium relative to peers. The trailing PE of 40.28x and forward PE of 36.56x are above the typical medical instruments sector average in the high-teens to low-twenties, and the EV/EBITDA of 26.97x is elevated versus low-to-mid-teens for peers. However, the PS ratio of 6.47x is near the bottom of its historical range (versus 29x-48x in 2021-2024), and the PE is below its 2021 peak of 59.22x. The market is paying a premium for West's superior profitability (37.74% gross margin, 20.09% operating margin) and its structural growth positioning. The valuation implies the market expects continued double-digit revenue growth and margin stability; any deviation could lead to multiple compression.
From a risk/reward perspective, WST is a good buy for investors with a medium-to-long-term horizon and tolerance for volatility. The stock offers 11.7% upside to the analyst average target of $407.56, with a high target of $459.00 implying 25.8% upside, supported by accelerating revenue growth (13.85% YoY in Q2 2026) and a strong buy consensus. However, the premium valuation at 40.28x trailing PE and the potential for margin compression pose risks. The biggest downside risk is a retest of the 52-week low of $223.83, representing a 38.7% decline, though the analyst low target of $340.00 suggests a more moderate bear case of -6.8%. For long-term investors comfortable with a beta of 1.135, WST offers a compelling way to gain exposure to the GLP-1 and biologics supply chain.
WST is more suitable for long-term investment (minimum 2-3 years) than short-term trading, given its growth stage, volatility, and earnings visibility. The company is in a structural growth phase driven by GLP-1 and biologics demand, with a beta of 1.135 indicating above-market volatility, and a low dividend yield of 0.31% (payout ratio 12.4%) means income is not a primary return driver. Earnings visibility is moderate, with analyst estimates for EPS of $14.01 and revenue of $4.42B, but quarterly fluctuations can be significant (e.g., the July 24 drop from $355.48 to $328.20). Short-term traders might exploit momentum around earnings, but the stock's premium valuation and high beta make it risky for short-term holding. A minimum holding period of 2-3 years allows investors to ride out volatility and benefit from the secular growth trend.